ICIrina A. Cheremisina

Irina A. Cheremisina

*This is an algorithmically generated author record based on publicly available information.

Irina A. Cheremisina has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Combination of Hyaluronic Acid, Chondroitin Sulphate, and Poloxamer 407 for the Prevention and Treatment of Radiation Esophagitis (Results of the RESOXX Multicenter Prospective Observational Study)

    by D. S. Romanov, E. I. Turyaeva, S. N. Novikov, S. V. Golub, M. A. Ilin, D. A. Balaeva, G. A. Garyaev, P. R. Chowdhury, I. A. Cheremisina, M. A. Getman, et al.

    Aim: to evaluate the efficacy of an oral medical device — a fixed combination of hyaluronic acid, chondroitin sulphate, and the bioadhesive agent poloxamer 407 (Alfasoxx), on the incidence, course, and severity of radiation esophagitis symptoms in patients undergoing external beam radiotherapy for a primary malignancy. Materials and methods. A total of 215 patients were enrolled in the study, of whom 210 were included in the statistical analysis. Patients were divided into two groups: a treatment group (patients with manifestations of radiation esophagitis at study entry) and a prophylaxis group (patients enrolled on the start date of external beam radiotherapy). Seventeen oncologists from nine Russian cities participated in the study. Assessment methods included clinical and demographic evaluation, analysis of the incidence and distribution of radiation esophagitis risk factors, evaluation of radiation esophagitis severity according to CTCAE v. 5.0, assessment of radiation dose delivered to the esophagus, Alfasoxx dosage accounting for compliance, evaluation of the time to radiation esophagitis onset and its duration, analysis of swallowing function using the EAT-10 questionnaire, assessment of overall health-related quality of life using the EORTC QLQ-C30 questionnaire, and monitoring of adverse events. Results. Manifestations of radiation esophagitis were observed in 68.5 % of patients in the prophylaxis group; therefore, radiation esophagitis did not develop in 31.5 % of patients. Compared with the prophylaxis group, patients in the treatment group experienced a more severe course of the disease, with a mean radiation esophagitis severity score of 0.83 ± 0.53 vs. 0.52 ± 0.25 (p < 0.001). The mean EAT-10 score at baseline differed from that in the treatment group. However, from Visit 2 onward, mean scores aligned and demonstrated identical dynamics. A similar distribution was observed for overall quality of life as assessed by the EORTC QLQ-C30 questionnaire. The significant difference observed at the first visit (68.73 ± 15.69 points in the prophylaxis group vs. 58.24 ± 16.04 points in the treatment group; p < 0.001) was leveled by Visit 4 among patients who developed radiation esophagitis (79.96 ± 10.91 points in the prophylaxis group and 81.25 ± 11.03 points in the treatment group). Only one adverse event was identified during Alfasoxx administration: mild nausea after intake. Conclusion. The prophylactic administration of Alfazox concurrently with the initiation of external beam radiotherapy reduces the mean severity of radiation-induced esophagitis and shortens the duration of symptom manifestation.

  • Effect of sulodexide on the walking, erectile and cognitive functions based on the findings of the ANDANTE study

    by M.R. Kuznetsov, I.а. Suchkov, A.V. Chupin, V.E. Barinov, S.V. Sapelkin, G.YU. Sokurenko, E.V. Barinov, E.P. Golovan’, I.A. Cheremisina, M.A. Get’MAn

  • The effect of sulodexide on the quality of life of patients with intermittent claudication: results of a multicenter observational study of ANDANTE

    by M.R. Kuznetsov, I.а. Suchkov, A.V. Chupin, V.E. Barinov, S.V. Sapelkin, G.YU. Sokurenko, E.V. Barinov, E.P. Golovan’, I.A. Cheremisina, M.A. Get’MAn

  • Open Access

    A Multicenter Prospective Observational Study to Examine the Experience of Using Phosphocreatine in Combination Therapy for Heart Failure Caused by Cancer Treatment. Rationale and Design of the Study

    by A. A. Safiullina, V. I. Potievskaya, M. V. Vitsenya, I. A. Cheremisina

    Enhanced cancer treatment efficacy has resulted in a significant increase in the number of cancer survivors after the cure of malignant tumors. However, cardiovascular morbidity, including chronic heart failure, has become the leading cause of death and decreased life expectancy among cancer survivors. This is due, in particular, to the cardiotoxic effects of anticancer drugs and associated factors. Cardioprotective approaches aim to reduce the incidence and severity of cardiotoxicity through the use of cardioprotective agents (e.g., dexrazoxane), liposomal drug delivery systems (e.g., liposomal doxorubicin), and optimization of drug administration schedules. Reducing the cardiotoxicity of cancer treatments is a clinically important goal. Phosphocreatine-based therapy represents a potentially valuable new strategy in this area. In this regard, the study "Multicenter prospective observational study to investigate the experience of using phosphocreatine in combination therapy for heart failure caused by cancer treatment" was initiated. This publication presents the protocol of the observational non-interventional NEOCARD study.


  • Open Access

    Effectiveness of neoton in patients with chronic heart failure depending on the left ventricular ejection fraction. Sub-analysis of the BYHEART study

    by S. N. Tereshchenko, I. A. Cheremisina, A. A. Safiullina

    Aim. To study the effectiveness of exogenous phosphocreatine (EPCr) therapy in patients with heart failure (HF) with reduced and mildly reduce dejection fraction (EF).Material and methods. The all-Russian prospective observational study BYHEART included 842 patients who underwent aEPCr therapy course. Before and after the course of EPCr therapy, the following studies were carried out: a questionnaire on the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the clinical assessment scale (CAS), transthoracic echocardiography with an assessment of the left ventricular EF, a 6-minute walk test, N-terminal pro-brain natriuretic peptide (NT-proBNP). All patients before the EPCr course received long-term optimal therapy for HF.Results. Data analysis was carried out for patients in groups with heart failure with reduced ejection fraction (HFrEF) and with mildly reduced ejection fraction (HFmrEF) within the group depending on the course of EPCr treatment: subgroup A — patients who received EPCr therapy less than 20 g/course and subgroup B — patients who received EPCr therapy ≥20 g/course. The results obtained demonstrate an increase in the quality of life and exercise tolerance, an improvement according to the CAS, a decrease in NT-proBNP levels, and an improvement in left ventricular systolic function in patients with both HFrEF and HFmrEF during the course of intravenous EPCr therapy.Conclusion. The use of EPCr is a promising tool in addition to optimal therapy in patients with HFrEF and HFmrEF.


  • Open Access

    The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART

    by Sergey N. Tereshchenko, Irina A. Cheremisina, Alfiya A. Safiullina, Терещенко Сергей Николаевич

    Aim. To study the efficacy and safety of exogenous phosphocreatine (EF) in patients with chronic heart failure (CHF). Materials and methods. The all-Russian prospective observational study BYHEART included 842 patients who were treated with EF. Before and after the course of EF therapy, the following studies were conducted: a questionnaire on the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and a clinical condition assessment scale (SHOCK), transthoracic echocardiography with an assessment of the left ventricular ejection fraction, a 6-minute walk test, determination of the level of pro-natriuretic N-terminal peptide (NT-proBNP), glomerular filtration rate. All patients before the course of EF received long-term optimal drug therapy of CHF. Results. Statistical analysis was carried out in the general group of patients (n=842), as well as in groups of patients A (n=418, the course of treatment of EF is less than 20 g /course) and group B (n=424, the course of treatment of EF is greater than or equal to 20 g/course). The results obtained demonstrate a positive effect of the use of the course of therapy of EF in patients with CHF on the quality of life (QOL), reverse left ventricular remodeling, functional class of CHF, as well as the concentration of NT-pro-BNP, especially in the group of patients who received more than 20 grams of the medication. Conclusion. The use of EF is a promising pharmacological method of treatment in addition to optimal drug therapy in patients with CHF.


  • Open Access

    Interim Results of the BYHEART Observational Study: Exogenous Phosphocreatine Effect on the Quality of life of Patients with Chronic Heart Failure

    by S. N. Tereschenko, N. B. Perepech, I. A. Cheremisina, V. N. Belov, Y. A. Vollis, A. A. Ispiriyan, E. A. Gridneva, A. A. Ismailova, M. N. Maltseva, E. H. Melnikova, et al.

    Aim      Improvement of quality of life is one of the most important goals for the treatment of patients with chronic heart failure (CHF). This study searched for ways to increase the efficiency of CHF treatment based on parameters of quality of life in CHF patients during and after the treatment with exogenous phosphocreatine (EP). Material and methods  The effect of a single course of EP treatment on quality of life of patients with functional class (FC) II-IV CHF with reduced or mid-range left ventricular ejection fraction was studied as a part of the all-Russia prospective observational study BYHEART. The presence of FC II-IV CHF and a left ventricular ejection fraction Results An interim data analysis showed that the course of EP treatment was associated with a significant improvement of quality-of-life indexes as determined by the Minnesota Living with Heart Failure Questionnaire (LHFQ) total score. These indexes significantly increased and remained at a satisfactory level for 6 mos. following completion of the treatment course. Also, the treatment significantly beneficially influenced the clinical condition of patients (heart failure severity scale), results of 6MWT, and the increase in left ventricular ejection fraction. Conclusion      The conclusions based on results of the interim analysis should be confirmed by results of the completed study. Complete results are planned to be published in 2022.